![Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies](http://www.tropicalgastro.com/uploads/Untitlnkged-30.jpg)
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma | PLOS ONE
![Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics](https://pubs.rsna.org/cms/10.1148/rg.2021210005/asset/images/medium/rg.2021210005.va.gif)
Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist | RadioGraphics
![Tumor Marker Usage and Medical Care Costs Among Older Early-Stage Breast Cancer Survivors | Journal of Clinical Oncology Tumor Marker Usage and Medical Care Costs Among Older Early-Stage Breast Cancer Survivors | Journal of Clinical Oncology](https://ascopubs.org/na101/home/literatum/publisher/asco/journals/content/jco/2015/jco.2014.59.33.issue-2/jco.2014.55.5409/20161107/images/medium/zlj00215-4672-t01.jpeg)
Tumor Marker Usage and Medical Care Costs Among Older Early-Stage Breast Cancer Survivors | Journal of Clinical Oncology
![CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/c2bd5005-c361-4918-a30a-59237934b956/gr1.gif)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
![IJMS | Free Full-Text | CA 19-9 Pancreatic Tumor Marker Fluorescence Immunosensing Detection via Immobilized Carbon Quantum Dots Conjugated Gold Nanocomposite IJMS | Free Full-Text | CA 19-9 Pancreatic Tumor Marker Fluorescence Immunosensing Detection via Immobilized Carbon Quantum Dots Conjugated Gold Nanocomposite](https://www.mdpi.com/ijms/ijms-19-01162/article_deploy/html/images/ijms-19-01162-sch003.png)